Concepedia

Publication | Closed Access

Phase I modular study of AZD6738, a novel oral, potent and selective ataxia telangiectasia Rad3-related (ATR) inhibitor in combination (combo) with carboplatin, olaparib or durvalumab in patients (pts) with advanced cancers

DOI

48

Citations

0

References

2016

Year

Timothy A. Yap, Matthew Krebs, S. Postel-Vinay, Yung‐Jue Bang, A. El-Khoueiry, Wassim Abida, Kevin J. Harrington, Raghav Sundar, L. Carter, Eduardo Castanon-Alvarez,
European Journal of Cancer

No additional data available for this publication yet. Check back later!